Zefiro Methane Corp. secured an $11.5 million contract to plug orphaned and end-of-life oil and gas wells for a state environmental department in the Great Lakes region. The work will be carried out from November 2026 to June 2029, with $3 million to be spent by mid-2027 and the remainder by 2029. This contract expands Zefiro's presence in key U.S. markets and follows a previous $19.6 million remediation contract awarded in Ohio. The company aims to leverage these multi-year contracts to optimize operations and drive long-term shareholder value amid strong federal and private sector demand.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
